Indications and uses
For treatment of acne
For treatment of acne
Wet face with warm water, apply cleanser and work into a lather, then gently massage over face in a circular motion. Avoid sensitive eye area. Rinse thoroughly and pat dry. If excessive drying occurs, use every other day. If going outside use a sunscreen.
Salicylic Acid 2%
Acne Treatment
For treatment of acne
For external use only. Do not use if you have very sensitive skin or are sensitive to salicylic acid.
avoid unnecessary sun exposure and use a sunscreen. Keep away from eyes lips and mouth. If contact occurs, rinse thoroughly with water. Irritation may develop such as redness, burning, itching peeling or possibly swelling. More frequent use or higher concentrations may aggravate such irritation. Mild irritation may be reduced by using the product less frequently. using this product in tandem with other topical acne treatments may increase dryness or cause irritation of the skin. If this occurs, only one medication should be used unless directed by a physician. If irritation becomes severe, or persists, discontinue use and consult a physician.
If swallowed, get medical help or contact a Poison Control Center immediately.
Wet face with warm water, apply cleanser and work into a lather, then gently massage over face in a circular motion. Avoid sensitive eye area. Rinse thoroughly and pat dry. If excessive drying occurs, use every other day. If going outside use a sunscreen.
Water, Sodium C14-16 Olefin Sulfonate, Cocamidopropryl Betaine, Sodium C12-15 Pareth-15 Sulfonate, Aloe Barbadensis Leaf Extract, Anthemis Nobilis flower extract, Chamomilla Recutita (Matricaria) Flower Extract, Linoleamidopropyl PG-Dimonium Chloride Phosphate, Disodium EDTA, Propylene Glycol, Butylene Glycol, Yellow 5 (CI191440), Red 40 (CI 16035), Sodium Chloride, Fragrance.
visit
www.specificbeauty.com or please call: (877) 358-1122
Information disponable en Espanol
Morning
Follow with Skin Brightening Serum and Daily Hydrating Lotion SPF 30
Evening Follow with Skin Brightening Serum and Night Treatment Complex
Rx Dermatologist designed regimen
*is not prescription strength
Acne Treatment Cleanser a salicylic acid wash gentle enough for daily use, yet tough enough to get into the pores to help reduce acne blemishes. Leaves the skin feeling soft and smooth, not tight and dry.
Specific Beauty is a dermatologist tested, designed and proven effective treatment line. The result of years of experience and expertise, it is specifically designed for multi-hued skin tones. This regimen contains products that were formulated to be used together so the final results are benefits that are clearly visible. When used as directed, Specific Beauty regimen will result in a more even skin tone, improved skin texture and leaves skin hydrated, brighter and more radiant. Perfect for all skin types.
H. Woolery-Lloyd, M.D.
Specific Beauty has a complete line of products that compliment each other
MORNING USE
STEP 1
Acne Treatment Cleanser
or
Daily Gentle Cleanser
S
TEP 2
Skin Brightening Serum
a breakthrough formula containing a multi-benefit complex of licorice, antioxidants and retinol
STEP 3
Daily Hydrating Lotion | SPF 30
A lightweight moisturizer with SPF 30, UVA/UVB Protection. This unique formula is rich in the powerful antioxidant Vitamin E.
EVENING USE
STEP 1
Acne Treatment Cleanser
or
Exfoliating Cleansing Cloths
STEP 2
Skin Brightening Serum
refer to morning use.
STEP 3
Night Treatment Complex
a night treatment that helps improve skin texture by delivering a dose of retinol to the skin.
USE AS NEEDED
Professional Moisture Complex
a patented moisture complex that helps restore the skins' protective moisture barrier. Ideal for all skin types.
In order to maintain the desired results, continued use of the complete Specific Beauty regimen is recommended.
Specific Beauty
for multi-hued skin tones
Clarifying Wash
Acne Treatment Cleansr
Step 1 Salicylic Acid 2% AM/PM
Rx Dermatologist Designed Regimen
Minimizes breakouts, gently cleanses, unclogs pores, and removes oil
PARABEN FREE
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 562600 | salicylic acid 2 % Medicated Liquid Soap | PSN | 4 |
| 562600 | salicylic acid 20 MG/ML Medicated Liquid Soap | SCD | 4 |
| 562600 | salicylic acid 2 % Facial Cleanser Toner | SY | 4 |
| 562600 | salicylic acid 2 % Facial Scrub | SY | 4 |
| 562600 | salicylic acid 2 % Medicated Liquid Soap | SY | 4 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 52295-207-67 | 2021-01-29 | C162847 | 48780-1 | ba0f9c33-39c9-a910-e053-dadaa90a0b85 | Specific Beauty Clarifying Wash Acne Treatment Cleanser |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 52295-207-67 | Specific Beauty Clarifying Wash Acne Treatment Cleanser | 200 mL in 1 BOTTLE | SOAP | 200 | 4 | |
| 52295-207-67 | Specific Beauty Clarifying Wash Acne Treatment Cleanser | 1 in 1 BOX | SOAP | 1 | 4 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| SALICYLIC ACID | ACTIVE INGREDIENT | O414PZ4LPZ | 2 | |
| SALICYLIC ACID | ACTIVE MOIETY | O414PZ4LPZ | 2 | |
| ALOE VERA LEAF | INACTIVE INGREDIENT | ZY81Z83H0X | 2 | |
| BUTYLENE GLYCOL | INACTIVE INGREDIENT | 3XUS85K0RA | 2 | |
| CHAMAEMELUM NOBILE FLOWER | INACTIVE INGREDIENT | O2T154T6OG | 2 | |
| CHAMOMILE | INACTIVE INGREDIENT | FGL3685T2X | 2 | |
| COCAMIDOPROPYL BETAINE | INACTIVE INGREDIENT | 5OCF3O11KX | 2 | |
| EDETATE DISODIUM | INACTIVE INGREDIENT | 7FLD91C86K | 2 | |
| FD&C YELLOW NO. 5 | INACTIVE INGREDIENT | I753WB2F1M | 2 | |
| LINOLEAMIDOPROPYL PG-DIMONIUM CHLORIDE PHOSPHATE | INACTIVE INGREDIENT | 5Q87K461JO | 2 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 2 | |
| SODIUM C12-15 PARETH-15 SULFONATE | INACTIVE INGREDIENT | 353VA59XH8 | 2 | |
| SODIUM C14-16 OLEFIN SULFONATE | INACTIVE INGREDIENT | O9W3D3YF5U | 2 | |
| SODIUM CHLORIDE | INACTIVE INGREDIENT | 451W47IQ8X | 2 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 52295-207 | 52295-207-67 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | INJECTION / INFILTRATION | 6 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / OPHTHALMIC | 10 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRAVENOUS | 28773 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CREAM / TOPICAL | 76000 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, COATED / ORAL | 16 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / DENTAL | 2 %w/w | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / SUBCUTANEOUS | 0.7 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / TRANSDERMAL | 500 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / SUBCUTANEOUS | 0.8 %w/v | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | TABLET, EFFERVESCENT / ORAL | 32 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / AURICULAR (OTIC) | 10 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | DROPS / ORAL | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INFILTRATION | 3535 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SYSTEM / IONTOPHORESIS | 0.1 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | PASTE / DENTAL | 0.5 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION, SOLUTION / INTRAVENOUS | 4000 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | LIQUID / INTRAVENOUS | 0.03 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CAPSULE / ORAL | 1072 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION/ DROPS / OPHTHALMIC | 0.75 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, DELAYED RELEASE / ORAL | 97 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SUSPENSION, EXTENDED RELEASE / ORAL | 40 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | DROPS / NASAL | NA | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SOLUTION / NASAL | 100 mg/100ml | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION, SOLUTION / SUBCUTANEOUS | 1.4 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SPRAY / NASAL | 30 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / SUBCUTANEOUS | 90 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | DROPS / ORAL | 200 mg/1ml | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | INJECTION, SUSPENSION / INTRAMUSCULAR | 1 mg | ||
| FD&C YELLOW NO. 5 | FD&C YELLOW NO. 5 | I753WB2F1M | SOLUTION / TOPICAL | 0.06 %w/w | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | JELLY / NASAL | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CAPSULE, COATED / ORAL | 25 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION/ DROPS / OPHTHALMIC | 0.75 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | GEL / VAGINAL | 10 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, FILM COATED / ORAL | 96 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SWAB / TOPICAL | 34.6 %w/w | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | LIQUID / ORAL | 0.5 mg/1ml | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SPONGE / TOPICAL | 40 %w/w | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | EMULSION / OPHTHALMIC | 0.3 %w/v | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SPRAY / RESPIRATORY (INHALATION) | 0.05 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / ORAL | 22602 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | INJECTION / SOFT TISSUE | 0.05 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRACAVITARY | 0.82 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / RESPIRATORY (INHALATION) | 108 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | EMULSION / TOPICAL | 8 %w/w | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SPRAY, METERED / NASAL | 4 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION / INTRAVENOUS | 0.9 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / SUBARACHNOID | 0.9 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / INTRAVASCULAR | NA | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | TABLET, DELAYED RELEASE / ORAL | 100 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION/ DROPS / AURICULAR (OTIC) | ADJ PH | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRAVASCULAR | 0.86 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INTRATHECAL | 131 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRACARDIAC | 70 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION / INTRALESIONAL | 13 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / OPHTHALMIC | 13 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SUSPENSION / SUBCUTANEOUS | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INTRACAUDAL | 210 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | CREAM / VAGINAL | 3 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION / INTRASYNOVIAL | 4 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRAMUSCULAR | 1486 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 85b68f04-a91c-f6a2-e053-2991aa0af9fd | dd28d1f0-7835-430a-84be-d92f03ce9176 | 2019-04-04 | Warnings | 85b68f04-a91c-f6a2-e053-2991aa0af9fd dd28d1f0-7835-430a-84be-d92f03ce9176 |
Adverse event summaries are temporarily unavailable. Other product information remains available.